Centene reports a rare loss as medical costs surge, and the stock hits a decade low

Centene Corp. reported a rare second-quarter net loss of $253 million, or an adjusted loss of 16 cents per share, significantly missing analyst expectations, as surging medical costs drove its health benefits ratio (HBR) to a five-year high of 93.0%. This increase was attributed to higher Medicaid payouts for behavioral and home health, high-cost drugs, and lower risk-adjustment revenue, despite overall revenue exceeding forecasts. The unexpected loss sent Centene's stock down 10.6% in premarket trading, extending its July decline to over 50% and pushing it to a decade low, making it the S&P 500's worst performer this year.

Analysis

Centene Corporation (CNC) reported a significant and unexpected second-quarter net loss of $253 million, a stark reversal from the $1.15 billion in net income a year prior. The adjusted loss of 16 cents per share dramatically missed the FactSet consensus estimate for an 11-cent profit, marking the company's first adjusted loss in over five years. The primary driver of this underperformance was a surge in medical costs, evidenced by the health benefits ratio (HBR) climbing to a five-year high of 93.0%, well above the 87.6% recorded last year and the 91.3% analyst forecast. Management attributed the elevated HBR to higher-than-anticipated Medicaid costs, particularly in behavioral and home health services and high-cost drugs, coupled with lower risk-adjustment revenue from its Marketplace business. This fundamental operational challenge overshadowed strong top-line performance, where total revenue grew 22.4% to $48.74 billion, beating expectations. However, declining membership in core Medicaid (-2.4%) and Medicare (-9.8%) segments raises concerns, despite growth in Commercial and Medicare PDP plans. The market's reaction has been severe, with the stock falling to a decade low after having already declined over 50% in July following the withdrawal of full-year guidance, cementing its position as the S&P 500's worst performer year-to-date.

Key Decisions for Investors

• Given the withdrawal of 2024 guidance and the magnitude of the earnings miss, investors should await the 2025 financial outlook from the upcoming earnings call before making any new capital allocation decisions.
• Monitor the post-earnings call for specific management plans to address the structural cost issues within the Medicaid business, as the sharp increase in the Health Benefits Ratio indicates a severe forecasting failure.
• The stock is a classic 'falling knife' scenario; while the valuation has dropped significantly, the fundamental deterioration and loss of management credibility present substantial near-term risks that outweigh the potential for a value play until a clear turnaround strategy is articulated and validated.
• Consider the extreme underperformance relative to the Health Care Select Sector SPDR ETF (-1.3% YTD) and the S&P 500 (+8.2% YTD) as a reflection of deep, company-specific issues rather than sector-wide headwinds.